American Thoracic Society - Sanofi Investor Call

• • Conclusions Dupilumab reduced the annualized rate of moderate-to-severe exacerbations by 30% compared to placebo Dupilumab improved patient reported lung function and patient reported outcomes: o 83 mL improvement in FEV₁ ○ Significant improvement in quality of life ○ Significant improvement in severity of symptoms Safety results were consistent with the known safety profile of dupilumab ATS 2023 32

View entire presentation